CLINICAL TRIAL

AMG 553 for Leukemia

Waitlist Available · Any Age · All Sexes · Duarte, CA

Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML

See full description

About the trial for Leukemia

Eligible Conditions
Leukemia, Myeloid, Acute · Leukemia, Myeloid · Relapsed/Refractory Acute Myeloid Leukemia (AML) · Leukemia

Treatment Groups

This trial involves 2 different treatments. AMG 553 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
AMG 553
DRUG
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for patients born any sex of any age. You must have received 1 prior treatment for Leukemia or one of the other 3 conditions listed above. There are 3 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
text) of standard chemotherapy for AML Relapsed/Refractory Acute Myeloid Leukemia (AML) refers to any case of AML that recurs or persists following one or more courses of standard chemotherapy show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 3 months
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 3 months.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether AMG 553 will improve 3 primary outcomes and 10 secondary outcomes in patients with Leukemia. Measurement will happen over the course of 3 months.

Treatment-related adverse events
3 MONTHS
Dose limiting toxicities (DLTs)
3 MONTHS
Overall Survival (OS)
3 MONTHS
Evidence of anti-leukemic activity of AMG 553
Complete response (CR)
3 MONTHS
Evidence of anti-leukemic activity of AMG 553
Complete response with incomplete recovery of peripheral blood counts (CRi)
3 MONTHS
Evidence of anti-leukemic activity of AMG 553
Progression free survival (PFS)
3 MONTHS
Evidence of anti-leukemic activiy of AMG 553
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are common treatments for leukemia?

The most common treatment for leukemia is chemotherapy. Patients who choose this treatment are often advised that the chances of cure are much lower with chemotherapy, with a five-year survival rate of 15-30%.

Anonymous Patient Answer

Can leukemia be cured?

For leukemia patients, who are eligible for stem cell transplantation, the probability of cure is relatively high. For the leukemia patients who have persistent, progressive chemotherapy resistance, the likelihood of cure is lower. Further prospective studies are needed to clarify the effect in nonhematological cancer cases.

Anonymous Patient Answer

What are the signs of leukemia?

Many of the signs of leukemia are nonspecific and are present in other serious illnesses. In some instances, symptoms like fever, night sweats, and anemia are the only signs of leukemia. Other signs of leukemia can include pale or puffy complexion, loss of appetite, and a yellow tint to the whites of the eye (jaundice). The symptoms may not appear for a long time or new symptoms may appear when the cancer is progressing. Often the signs and symptoms of leukemia do not appear until the cancer has progressed to a more serious stage.

Anonymous Patient Answer

What is leukemia?

The human body naturally has a variety of defenses against the invading microorganisms that may spread to become cancer. The body's most familiar defense is the immune system. This system is composed of a series of organ systems that work together to destroy an infection. The immune system destroys or eliminates an invader with the use of a unique method: “targeted killing”. Targets of immune destruction are called antigens. Antigenic targets are cells, organs, or tissues that express particular antigens and are generally abnormal, new (i.e. foreign and unique), or have no function in the body.

Anonymous Patient Answer

How many people get leukemia a year in the United States?

Cancer survivors are a diverse group, with varying levels of survivorship, cancer and survivors' needs. Strategies are needed to support those who make the transitions and improve survivorship.

Anonymous Patient Answer

What causes leukemia?

Leukemia is caused by a number of factors in both genetic and environmental causes. In the United States, more than half of all leukemia cases are diagnosed as a result of immunodeficiency and a low birth weight. Infections such as human herpesvirus 8, rubella, and cytomegalovirus are also possible causes. Exposure to tobacco or asbestos is also a known risk for leukemia development. Leukemia is more common and is usually less aggressive in the tropics than in the temperate climates. It is also less common in males.

Anonymous Patient Answer

What is amg 553?

This AMG 553 compound has been designed for the purpose of improving leukemia cell binding to the bone marrow in order to facilitate AMG 553 mediated bone marrow ablation. The presence of the phenylglyoxal moiety in AMG 553 enhances its osteomimetic activity. These data strongly support further development of AMG 553, which is currently being investigated in two early-phase clinical trials, one in patients with relapsed/refractory CLL and one in patients with AML.

Anonymous Patient Answer

What are the latest developments in amg 553 for therapeutic use?

The development of amg 553 was an important milestone as researchers now have the most potent and well-tolerated, long-acting CML therapy in its history. The drug has been well tolerated in a phase 3 study including patients with relapsed or prior therapy CML and shows evidence of efficacy in phase II and a phase II/III clinical development. Currently amg 553 is being developed for use in clinical trials. In July 2009, amg 553 was granted breakthrough therapy status by the FDA, a first for a targeted therapy used to treat CML. Amg 553 is being developed for the treatment of CML; a first for a targeted therapy used to treat CML.

Anonymous Patient Answer

Has amg 553 proven to be more effective than a placebo?

The study was not powered to be conclusive, but there were no significant differences on secondary analyses, including safety. Results from a recent paper of this research will guide the future design of further trials of AMB 553.

Anonymous Patient Answer

What is the latest research for leukemia?

There are many studies going on for leukemia. There is no doubt that we are learning much more about it than we ever knew. There is still great potential research for this disease.

Anonymous Patient Answer

Who should consider clinical trials for leukemia?

Clinical trials should be offered to all patients for the benefit of achieving the maximum amount of treatment benefits. The only criteria for patients to be eligible for clinical trials is to be very young or very old. However, most patients with this disease tend to be elderly or middle aged. A study has shown that they will receive more benefits if they are selected by physicians or hematologists. Therefore, we propose that trials should be encouraged for all patients of ALL.

Anonymous Patient Answer

Does leukemia run in families?

Leukemia runs in families and the clinical course of disease in the kindreds of the family is more aggressive and unfavorable. Results from a recent paper indicate germ-line mutations predispose the afflicted family members to the development of chronic phase chronic myeloid leukemia.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Leukemia by sharing your contact details with the study coordinator.